A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction

Journal of Biopharmaceutical Statistics

Volumn 18, Issue 6, 2008, Pages 1063-1083

  Yu, Menggang ^a   Kim, Seongho ^a   Wang, Zhiping ^a   Hall, Stephen ^a   Li, Lang ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Area under the concentration curve ratio (AUCR); Bayesian hierarchical model; Drug drug interaction (DDI); Meta analysis; Monte Carlo Markov chain (MCMC); Pharmacokinetics (PK); Prediction

Indexed keywords

KETOCONAZOLE; MIDAZOLAM;

AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; MALE; MONTE CARLO METHOD; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIMULATION; STATISTICAL MODEL;

ADMINISTRATION, ORAL; BAYES THEOREM; BIAS (EPIDEMIOLOGY); COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; KETOCONAZOLE; MALE; MARKOV CHAINS; MIDAZOLAM; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; REPRODUCIBILITY OF RESULTS;

EID: 57349155114     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400802369004     Document Type: Article

References (39)

1. Bourrie, M., Meunier, V., Berger Y., Fabre G. (1996). Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmaco. Exper. Ther. 277:321-332.
2. Breslow, N. E., Clayton, D. G. (1993). Approximate inference in generalized linear mixed model. J. Am. Stat. Assoc. 88:9-25.
3. Chien, J. Y., Lucksiri, A., Ernest, C. S., Gorski, J. C., Wrighton, S. A., Hall, S. D. (2006). Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab. Dispos. 34:1208-1219.
4. Cleary, J. D., Taylor, J. W., Chapman, S. W. (1992). Itraconazole in antifungal therapy. Ann. Pharmacother. 26:502-509.
5. Daneshmend, T. K., Warnock, D. W., Turner, A., Roberts, C. J. (1981). Pharmacokinetics of ketoconazole in normal subjects. J. Antimicrob. Chemother. 8:299-304.
6. Daneshmend, T. K., Warnock, D. W., Ene, M. D., Johnson, E. M., Parker, G., Richardson, M. D., Roberts, C. J. (1983). Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. J. Antimicrob. Chemother. 12:185-188.
7. Daneshmend, T. K., Warnock, D. W., Ene, M. D., Johnson, E. M., Potten, M. R., Richardson, M. D., Williamson, P. J. (1984). Influence of food on the pharmacokinetics of ketoconazole. Antimicrob. Agents Chemother. 25:1-3.
8. Davidian, M., Giltinan, D. M. (1995). Nonlinear Models for Repeated Measurment Data. New York: Chapman and Hall.
9. de Waziers, I., Cugnenc, P. H., Yang, C. S., Leroux, J. P., Beaune, P. H. (1990). Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J. Pharmacol. Exp. Ther. 253:387-394.
10. FDA (1999). Bioequivalence Reviews. http://www.fda.gov/cder/foi/anda/99/ 75-273_Ketoconazole_bioeqr.pdf
11. FDA (2006). Drug Drug Interaction Guideline. http://www.fdagov/cber/ gdlns/interactionpdf.
12. Gascoigne, E. W., Barton, G. J., Michaels, M., Meuldermans, W., Heykans, J. (1981). The kinetics of ketoconazole in animals and man. Clin. Res. Rev. 1:177-187.
13. Gelman, A., Rubin, D. B. (1992). Inference from iterative simulation using multiple sequences. Statist. Sci. 7:457-472.
14. Gibbs, M. A., Thummel, K. E., Shen, D. D., Kunze, K. L. (1999). Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos. 27(2):180-187.
15. Hastings, W. K. (1970). Monte Carlo sampling methods using Markov chains and their applications. Biometrika 57:97-109.
16. Huang, Y. C., Colaizzi, J. L., Bierman, R. H., Woestenborghs, R., Heykants, J. (1986). Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob. Agents Chemother. 30:206-210.
17. Ikkola, K. T., Backman, J. T., Neuvonen, P. J. (1994). Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55:481-485.
18. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., Sugiyama, Y. (1998). Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol. Rev. 50:387-412.
19. Lam, Y. W., Alfaro, C. L., Ereshefsky, L., Miller, M. (2003). Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone. J. Clin. Pharmacol. 43:1274-1282.
20. Lee, J. I., Chaves-Gnecco, D., Amico, J. A., Kroboth, P. D., Wilson, J. W., Frye, R. F. (2002). Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin. Pharmacol. Ther. 72:718-728.
21. Li, L., Brown, M. B., Lee, K. H., Gupta, S. (2002). Estimation and inference for a spline-enhanced population pharmacokinetic model. Biometrics 58:601-611.
22. Li, L., Lin, X., Brown, M., Gupta, S., Lee, K. H. (2004). A population pharmacokinetic model with time-dependent covariates measured with errors. Biometrics 60:451-460.
23. Li, L., Yu, M., Chin, R., Lucksiri, A., Flockhart, D., Hall, S. (2007). Drug-drug interaction prediction: a Bayesian meta-analysis approach. Statistics in Medicine 26:3700-3721.
24. Martinez-Jorda, R., Rodriguez-Sasianin, J. M., Calvo, R. (1990). Serum binding of ketoconazole in health and disease. Int. J. Clin. Pharmacol. Res. 5:271-276.
25. McCrea, J., Prueksaritanont, T., Gertz, B. J., Carides, A., Gillen, L., Antonello, S., Brucker, M. J., Miller-Stein, C., Osborne, B., Waldman, S. ( 1999). Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J. Clin. Pharmacol. 39:1212-1220.
26. Molenberghs, G., Verbeke, G. (2005). Models for Discrete Longintudinal Data. New York: Springer.
27. Monahan, B. P., Ferguson, C. L., Killeavy, E. S., Lloyd, B. K., Troy, J., Cantilena, L. R., Jr. (1990). Torsades de pointes occurring in association with terfenadine use. Jama 264:2788-2790.
28. Okuda, H., Nishiyama, T., Ogura, K., Nagayama, S., Ikeda, K., Yamaguchi, S., Nakamura, Y., Kawaguchi, Y., Watabe, T. (1997). Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab. Dispos. 25:270-273.
29. Price, P. S., Conolly, R. B., Chaisson, C. F., Gross, E. A., Young, J. S., Mathis, E. T., Tedder, D. R. (2003). Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33:469-503.
30. Rowland, M., Tozer, T. N. (1995). Clinical Pharmacokinetics Concept and Applications. London: Lippincott Williams & Wilkins.
31. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F. P. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423.
32. Tsunoda, S. M., Velez, R. L., von Moltke, L. L., Greenblatt, D. J. (1999). Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clin. Pharmacol. Ther. 66:461-471.
33. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Harmatz, J. S., Shader, R. I. (1994). In vitro prediction of the terfenadine-ketoconazole pharmacokinetics interaction. J. Clin. Pharmacol. 34:1222-1227.
34. von Moltke, L. L., Greenblatt, D. J., Schmider, D. J., Duan, S. X., Wright, C. E., Harmatz, J. S., Shader, R. I. (1996). Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxitine, norfluxetine, and by azole antifungal agents. J. Clin. Pharmacol. 36:783-791.
35. Wakefield, J. C., Rahman, N. (2000). The combination of population pharmacokinetic studies. Biometrics 56:263-270.
36. Watabe, T. (1996). Strategic proposals for predicting drug-drug interactions during new drug development: Based on sixteen deaths caused by interactions of the new antiviral sorivudine with 5-fluorouracil prodrugs. J. Toxicol. Sci. 21:299-300.
37. Wolfinger, R., O'Connell, M. (1993). Generalized linear mixed models: a pseudo-likelihood approach. J. Stat. Comp. Sim. 48:233-243.
38. Wrighten, S. A., Ring, B. J. (1994). Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res. 11:921-924.
39. Yang, J., Kjellsson, M., Rostami-Hodjegan, A., Tucker, G. T. (2003). The effects of dose staggering on metabolic drug-drug interactions. Eur. J. Pharm. Sci. 20:223-232.